Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Werewolf Therapeutics (HOWL) Retained Earnings (2021 - 2025)

Werewolf Therapeutics (HOWL) has disclosed Retained Earnings for 5 consecutive years, with -$467.0 million as the latest value for Q3 2025.

  • On a quarterly basis, Retained Earnings fell 18.48% to -$467.0 million in Q3 2025 year-over-year; TTM through Sep 2025 was -$467.0 million, a 18.48% decrease, with the full-year FY2024 number at -$414.6 million, down 20.49% from a year prior.
  • Retained Earnings was -$467.0 million for Q3 2025 at Werewolf Therapeutics, down from -$450.7 million in the prior quarter.
  • In the past five years, Retained Earnings ranged from a high of -$153.8 million in Q1 2021 to a low of -$467.0 million in Q3 2025.
  • A 5-year average of -$327.9 million and a median of -$323.8 million in 2023 define the central range for Retained Earnings.
  • Peak YoY movement for Retained Earnings: crashed 74.46% in 2022, then fell 12.18% in 2023.
  • Werewolf Therapeutics' Retained Earnings stood at -$252.9 million in 2021, then decreased by 21.28% to -$306.7 million in 2022, then fell by 12.18% to -$344.1 million in 2023, then fell by 20.49% to -$414.6 million in 2024, then dropped by 12.65% to -$467.0 million in 2025.
  • Per Business Quant, the three most recent readings for HOWL's Retained Earnings are -$467.0 million (Q3 2025), -$450.7 million (Q2 2025), and -$432.7 million (Q1 2025).